Profilo
Dr. Bianca Brundel is Chief Scientific Officer at NYKEN BV.
He received his graduate degree from the University of Amsterdam and a doctorate degree from the University of Groningen.
Precedenti posizioni note di Bianca Brundel
Società | Posizione | Fine |
---|---|---|
Nyken BV
Nyken BV Pharmaceuticals: GenericHealth Technology Nyken BV develops heat-shock-protein drugs for treatment of chronic diseases. Its products include NYK-1001, a drug that is used for the treatment of gastric discomfort and gastric bleeding in China, Japan, and internationally, NYK-1005, a chemical derivative that is used for atrial myocyte screening and drug identifying discovery system and NYK-1007, an early drug candidate used in heat shock proteins. The company was founded by Herman Steen in 2009 and is headquartered in Groningen, the Netherlands. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Bianca Brundel
University of Amsterdam | Graduate Degree |
University of Groningen | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Nyken BV
Nyken BV Pharmaceuticals: GenericHealth Technology Nyken BV develops heat-shock-protein drugs for treatment of chronic diseases. Its products include NYK-1001, a drug that is used for the treatment of gastric discomfort and gastric bleeding in China, Japan, and internationally, NYK-1005, a chemical derivative that is used for atrial myocyte screening and drug identifying discovery system and NYK-1007, an early drug candidate used in heat shock proteins. The company was founded by Herman Steen in 2009 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Bianca Brundel